Specifically, focusing on the aggregate effect of LoF variants in a gene-based burden test scheme for the prioritized PCTs, revealed significant (P < 2.75E-06) associations with higher values for corneal integrity (targeting MAP3K11) and increased risk for kidney disease and related depression symptoms (targeting PKD2). Here, MAP3K11 is linked to depressive symptom measurement.